Recent insights into the role of dipeptidyl aminopeptidase IV (DPIV) and aminopeptidase N (APN) families in immune functions

Clinical Chemistry and Laboratory Medicine

Volumn 47, Issue 3, 2009, Pages 253-261

  Ansorge, Siegfried ^a   Bank, Ute ^a   Heimburg, Anke ^a   Helmuth, Martin ^a   Koch, Gudrun ^a   Tadje, Janine ^a   Lendeckel, Uwe ^b   Wolke, Carmen ^b   Neubert, Klaus ^c   Faust, Jürgen ^c   Fuchs, Petra ^c   Reinhold, Dirk ^b   Thielitz, Anja ^b   Täger, Michael ^a  

^a IMTM GmbH   (Germany)

^b OTTO VON GUERICKE UNIVERSITY   (Germany)

^c MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Aminopeptidase N (APN); Cytokines; Dermal diseases; Dipeptidyl peptidase IV (DPIV); DPIV like enzymes; Immune system; Inflammatory diseases; PETIR

Indexed keywords

DIPEPTIDYL PEPTIDASE; DIPEPTIDYL PEPTIDASE 8; DIPEPTIDYL PEPTIDASE 9; DIPEPTIDYL PEPTIDASE IV; FIBROBLAST ACTIVATION PROTEIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; MICROSOMAL AMINOPEPTIDASE; SERINE PROTEINASE; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

CD4+ CD25+ T LYMPHOCYTE; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CYTOKINE PRODUCTION; DNA SYNTHESIS; ENZYME INHIBITION; ENZYME LOCALIZATION; ENZYME SPECIFICITY; FIBROBLAST; IMMUNE RESPONSE; INFLAMMATORY DISEASE; KERATINOCYTE; LYMPHOCYTE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SKIN INFLAMMATION; TH1 CELL; TH2 CELL; TISSUE DISTRIBUTION;

ANIMALS; ANTIGENS, CD13; ANTIGENS, CD26; HUMANS; PROTEASE INHIBITORS; SKIN DISEASES;

EID: 63849287732     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2009.063     Document Type: Review

References (42)

1. Gorrell MD. Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders. Clin Sci 2005;108:277-92.
2. Sedo A, Malik R. Dipeptidyl peptidase IV-like molecules: homologous proteins or homologous activities? Biochim Biophys Acta 2001;1550:107-16.
3. Maes M, Dubois V, Brand I, Lambair AM, Van der Veken P, Augustyns K, et al. Dipeptidyl peptidase 8/9-like activity in human leukocytes. J Leukoc Biol 2007;81:1-7.
4. Lambeir AM, Durinx C, Scharpe S, De Meester I. Dipeptidyl- peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci 2003;40:209-94.
5. Maes M, Scharpe S, De Meester I. Dipeptidyl peptidase II (DPPII), a review. Clin Chim Acta 2007;380:31-49.
6. Kähne T, Lendeckel U, Wrenger S, Neubert K, Ansorge S, Reinhold D. Dipeptidyl peptidase IV: a cell surface peptidase involved in regulating T cell growth (review). Int J Mol Med 1999;4:3-15.
7. Abbott CA, Gorrell M. The family of CD26/DPIV and related ectopeptidases. In: Langner J, Ansorge S, editors. Ectopeptidases. CD13/aminopeptidase N and CD26/ dipeptidylpeptidase IV in medicine and biology. New York: Kluwer Academic/Plenum Publishers, 2002:171-95.
8. Lendeckel U, Arndt M, Frank K, Wex T, Ansorge S. Role of alanyl aminopeptidase in growth and function of human T cells (review). Int J Mol Med 1999;4:17-27.
9. Albiston L, Ye S, Chai SY. Membrane bound members of the M1 family: more than minopeptidases. Protein Pept Lett 2004;11:491-500.
10. Riemann D, Kehlen A, Langner J. CD13 - not just amarker in leukemia typing. Immunol Today 1999;20:83-8.
11. Lendeckel U, Arndt M, Firla B, Wolke C, Wex T, Ansorge S. CD13/APN in haematopoietic cells - expression, function, regulation, and clinical aspects. In: Langner J, Ansorge S, editors. Ectopeptidases. CD13/aminopeptidase N and CD26/dipeptidylpeptidase IV in medicine and biology. New York: Kluwer Academic/Plenum Publishers, 2002:25-49.
12. Fournie-Zaluski M, Roques BP. New selective aminopeptidase N inhibitors as potential therapeutics. In: Langner J, Ansorge S, editors. Ectopeptidases. CD13/aminopeptidase N and CD26/dipeptidylpeptidase IV in medicine and biology. New York: Kluwer Academic/Plenum Publishers, 2002:51-94.
13. Lendeckel U, Bukowska A, Lä ttig JH, Brandt W. Alanylaminopeptidases in human T cells. In: Hooper NM, Lendeckel U, editors. Aminopeptidases in biology and disease. New York: Kluwer Academic/Plenum Publishers, 2004:25-50.
14. Thompson MW, Hersh LB. The puromycin-sensitive aminopeptidase. In: Hooper, NM, Lendeckel U, editors. Aminopeptidases in biology and disease. New York: Kluwer Academic/Plenum Publishers, 2004:1-15.
15. Bukowska A, Tadje J, Arndt M, Wolke C, Kähne T, Bartsch J, et al. Transcriptional regulation of cytosol and membrane alanyl-aminopeptidase in human T cell subsets. Biol Chem 2003;384:657-65.
16. Tholander F, Wetterholm A, Haeggström JZ. Leukotriene A4 hydrolase. In: Hooper NM, Lendeckel U, editors. Aminopeptidases in biology and disease. New York: Kluwer Academic/Plenum Publishers, 2004:83-112.
17. Ansorge S, Reinhold D. Immune peptides related to dipeptidyl aminopeptidase IV/CD26. In: Kastin AJ, editor. Handbook of biologically active peptides. New York: Elsevier/Academic Press, 2006:567-72.
18. Schö n E, Mansfeld HW, Demuth HU, Barth A, Ansorge S. The dipeptidyl peptidase IV, a membrane enzyme involved in the proliferation of T lymphocytes. Biomed Biochim Acta 1985;44:K9-15.
19. Reinhold D, Bank U, Bü hling F, Lendeckel U, Faust J, Neubert K, et al. Inhibitors of dipeptidyl peptidase IV induce secretion of transforming growth factor-beta 1 in PWM-stimulated PBMC and T cells. Immunology 1997; 91:354-60.
20. Steinbrecher A, Reinhold D, Quigley L, Gado A, Tresser N, Izikson L, et al. Targeting dipeptidyl peptidase IV (CD26) suppresses autoimmune encephalomyelitis and up-regulates TGF-beta 1 secretion in vivo. J Immunol 2001;166:2041-8.
21. Korom S, De Meester I, Stadlbauer TH, Chandraker A, Schaub M, Sayegh MH, et al. Inhibition of CD26/dipeptidyl peptidase IV activity in vivo prolongs cardiac allograft survival in rat recipients. Transplantation 1997;63: 1495-500.
22. Ansorge S, Schö n E, Kunz D. Membrane-bound peptidases of lymphocytes: functional implications. Biomed Biochim Acta 1991;50:799-807.
23. Bank U, Heimburg A, Helmuth M, Stefin S, Lendeckel U, Reinhold D, et al. Triggering endogenous immunosuppressive mechanisms by combining targeting of dipeptidyl peptidase IV (DPIV/CD26) and aminopeptidase N (APN/CD13) - a novel approach for the treatment of inflammatory bowel disease. Int Immunopharmacol 2006;6:1925-34.
24. Bank U, Tadje J, Tä ger M, Wolke C, Bukowska A, Ittenson A, et al. Inhibition of alanyl-aminopeptidase on CD4qCD25q regulatory T-cells enhances expression of FoxP3 and TGF-β1 and ameliorates acute colitis in mice. Int J Mol Med 2007;20:483-93.
25. Marguet D, Baggio L, Kobayashi T, Bernard T, Pierres AM, Nielsen M, et al. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc Natl Acad Sci USA 2000;97:6874-9.
26. H17 cells in development: an updated view of their molecular identity and genetic programming. Nat Rev Immunol 2008;8:337-48.
27. Schö n E, Born I, Demuth H, Faust J, Neubert K, Steinmetzer T, et al. Dipeptidyl peptidase IV in the immune system - effects of specific enzyme inhibitors on activity of dipeptidyl peptidase IV and proliferation of human lymphocytes. Biol Chem Hoppe-Seyler 1991;372:305-11.
28. Lankas GR, Leiting B, Roy RS, Eiermann GJ, Beconi MG, Biftu T, et al. Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes. Potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes 2005;54:2988-94.
29. Van der Veken P, Soroka A, Brandt I, Chen Y, Maes M, Lambeir A, et al. Irreversible inhibition of dipeptidyl peptidase 8 by dipeptide-derived diaryl phosphonates. J Med Chem 2007;50:5568-70.
30. Senten K, Van der Veken P, Bal G, De Meester I, Lambeir AM, Scharpe S, et al. Development of potent and selective dipeptidyl peptidase II inhibitors. Bioorg Med Chem Lett 2002;12:2825-8.
31. Edosada CY, Quan C, Wiesmann C, Tran T, Sutherlin D, Reynolds M, et al. Selective inhibition of fibroblast activation protein protease based on dipeptide substrate specificity. J Biol Chem 2006;281:7437-44.
32. Lendeckel U, Arndt, M, Bukowska A, Tadje J, Wolke C, Kähne T, et al. Synergistic action of DPIV and APN in regulation of T cell function. Adv Exp Med Biol 2003;524:123-31.
33. Wolke C, Tadje J, Bukowska A, Tä ger M, Bank U, Ittenson A, et al. Assigning the phenotype of natural regulatory T-cell to human T-cell line, KARPAS-299. Int J Mol Med 2006;17:275-8.
34. Lendeckel U, Arndt M, Frank K, Spiess A, Reinhold D, Ansorge S. Modulation of wnt-5a expression by actinonin: linkage of APN to the wnt-pathway? Adv Exp Med Biol 2000;477:35-41.
35. Li AG, Koster MI, Wang X-Y. Roles of TGFβ signaling in epidermal/appendage development. Cytokine Growth Factor Rev 2003;14:99-111.
36. Fathke C, Wilson L, Shah K, Kim B, Hocking A, Moon R, et al. Wnt signalling induces epithelial differentiation during cutaneous wound healing. BMC Cell Biol 2006;7:4.
37. Sakaguchi S, Ono M, Setoguchi R, Yagi H, Hori S, Fehervari Z, et al. Foxp3 CD25qCD4q natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev 2006;212:8-27.
38. Thielitz A, Bukowska A, Wolke C, Vetter R, Lendeckel U, Wrenger S, et al. Identification of extra- and intracellular alanyl aminopeptidases as new targets to modulate keratinocyte growth and differentiation. Biochim Biophys Res Commun 2004;321:795-801.
39. Thielitz A, Reinhold D, Vetter R, Bank U, Helmuth M, Wrenger S, et al. Inhibitors of dipeptidyl peptidase and aminopeptidase N target major pathogenetic steps in acne initiation. J Invest Dermatol 2007;127:1042-51.
40. Thielitz A, Vetter RW, Schultze B, Wrenger S, Simeoni L, Ansorge S, et al. Inhibitors of dipeptidyl peptidase IVlike activity effects in normal and keloid-derived skin fibroblast. J Invest Dermatol 2008;128:855-66.
41. Thielitz A, Ansorge S, Bank U, Tä ger M, Wrenger S, Gollnick H, et al. The ectopeptidases dipeptidyl peptidase IV (DPIV) and aminopeptidase N (APN) and their related enzymes as possible targets in the treatment of skin diseases. Front Biosci 2008;13:2364-75.
42. Boyman O, Hefti HP, Conrad C, Nickoloff BJ, Suter M, Nestle FO. Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-α. J Exp Med 2004; 199:731-6.